Weekly Recap: FY2026 revenue guide raised and Anthropic model review

Twist Bioscience Corp. (NASDAQ:TWST) raised FY2026 revenue guidance to $456—457M, aims for adjusted EBITDA breakeven in Q4 after expanding its long-sequence gene catalog and issuing about $300M equity, and will independently evaluate protein designs from Anthropic’s Claude Opus 4.8 and Mythos Previ…